Abliva - Gearing Up For KL1333’s Pivotal Study
With Abliva on the brink of advancing KL1333 to the final stage of clinical development, we provide an update to the investment thesis. Since May, the company has reported positive first-in-human data for KL1333, used that data to design a registrational P2/3 study, received validation from the FDA on their dual endpoint and submitted and received approval for an IND. The next step is to secure financing for the ~2 years to run the trial, which we estimate will require $30-40m, giving financial runway to the end of 2023. Please contact Naresh Chouhan ( ) for access to the full note and our initiation
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.